Market revenue in 2023 | USD 132.7 million |
Market revenue in 2030 | USD 171.5 million |
Growth rate | 3.7% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 38.06% in 2023. Horizon Databook has segmented the Canada neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
According to Life Sciences in British Columbia: Sector Profile, published in June 2020, Canada is among the top three locations to conduct clinical trials globally. It states that multinational pharmaceutical companies conduct a large portion of their clinical trials in Canada, as the country has a world-class clinical trials environment.
Moreover, in June 2022, the Canadian Minister of Health stated that it is going to launch a clinical research initiative in the country to increase clinical trial capacity. These factors are likely to contribute to market growth in Canada over the forecast period.
The researchers in the country are actively developing promising treatments for various neurological disorders. For instance, in October 2020, University Health Network in Toronto stated that it is developing the world’s first treatment for Parkinson’s disease Such initiatives are likely to promote the market growth in Canada.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Canada neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account